NWPF

News ArchivesRead News

Altered cells deliver Parkinson’s therapy to brain

Tuesday December 27, 2005

Dec 27, 2005 (Reuters Health) - Genetically modified nerve ’progenitor’ cells can be used as mini-pumps to deliver nerve growth factor to the brain, a new study in animals shows.

The results suggest such an approach could be used to treat Parkinson’s disease and other brain diseases in humans, Dr. Clive D. Svendsen of the University of Wisconsin-Madison and colleagues report.

A nerve growth factor called "glial cell line-derived neurotrophic factor" (abbreviated to GDNF) has been shown to protect dopamine-producing neurons, which are lost in Parkinson’s disease, Svendsen and his team note in the research journal Gene Therapy.

In fact, it’s safe to infuse GDNF into brain regions of patients with Parkinson’s disease, according to some studies, and it seems effective. However, delivering the drug in this fashion is complex and only reaches a single point in the brain.

In the current study, using rats with symptoms akin to Parkinson’s disease, the researchers investigated the effect of human neural progenitor cells engineered to produce GDNF.

The rats were transplanted with the modified cells, and after two weeks these were seen to have migrated to affected areas and to be secreting enough GDNF to extend the survival of dopamine neurons and promote outgrowth of nerve fibers.

By five weeks post-transplant, the animals showed a "strong trend toward functional improvement," and at eight weeks the cells were still releasing the growth factor.

Tests in elderly monkeys showed the cells survived and continued to release GDNF for three months after transplant. None of the animals in the studies developed brain tumors.

Svendsen and his colleagues conclude that their results "show that combining human progenitor cell therapy with ... gene therapy is a powerful approach to the future treatment of Parkinson’s disease and other neurological conditions."

Recent News

Aug 24 - Study Details Process Involved in Parkinson’s Disease
Aug 20 - Two proteins work together to help cells eliminate trash; Parkinson's may result
Aug 17 - Scientists visualize critical part of basal ganglia pathways
Aug 17 - VA benefits office seeks all vets exposed to Agent Orange
Aug 12 - New, rapid dementia screening tool rivals 'gold standard' clinical evaluations
Aug 11 - Strolling in Seaside, fighting Parkinson's
Aug 11 - Scientists probing molecular origins of Parkinson's disease highlight two proteins
Aug 11 - Could Chocolate Help To Ease Parkinson’s Disease?
Aug 10 - Take 2: Why Seattle should try to replicate Spokane’s 3-on-3 Hoopfest success
Aug 10 - Book Review: A voyage into Parkinson’s disease, led by patient and journalist
Aug 10 - Parkinson's could be slowed with existing drug
Aug 7 - Opinion: Why modern life is making dementia in your 40s more likely
Aug 3 - Software Turns Smartphones into Tools for Medical Research
Jul 31 - Innovative Technology Using Dragonflies Might Offer Insights Into Human Brain Function
Jul 27 - Low-dose lithium reduces side effects from most common treatment for Parkinson's disease
Jul 27 - Opinion: Parkinson's disease creating class of workers who fear for their jobs: PennLive letters
Jul 22 - Parkinson's: Diabetes drug may offer clue to treatment
Jul 19 - Alzheimer's Drugs in the Works Might Treat Other Diseases, Too
Jul 17 - Parkinson's disease may be treatable with antimalaria drugs
Jul 16 - Virtual research studies feasible